Your browser doesn't support javascript.
loading
Release of ranibizumab using a porous poly(dimethylsiloxane) capsule suppressed laser-induced choroidal neovascularization via the transscleral route.
Nagai, Nobuhiro; Daigaku, Reiko; Motoyama, Remi; Kaji, Hirokazu; Abe, Toshiaki.
Affiliation
  • Nagai N; Division of Clinical Cell Therapy, United Centers for Advanced Research and Translational Medicine (ART), Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, 980-8575, Japan. nagai@med.tohoku.ac.jp.
  • Daigaku R; Division of Clinical Cell Therapy, United Centers for Advanced Research and Translational Medicine (ART), Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, 980-8575, Japan.
  • Motoyama R; Division of Clinical Cell Therapy, United Centers for Advanced Research and Translational Medicine (ART), Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, 980-8575, Japan.
  • Kaji H; Department of Biomechanics, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, 2-3-10 Kanda-Surugadai, Chiyoda, Tokyo, 101-0062, Japan.
  • Abe T; Division of Clinical Cell Therapy, United Centers for Advanced Research and Translational Medicine (ART), Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, 980-8575, Japan.
J Mater Sci Mater Med ; 34(1): 5, 2022 Dec 31.
Article in En | MEDLINE | ID: mdl-36586040

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Choroidal Neovascularization / Ranibizumab Limits: Animals Language: En Journal: J Mater Sci Mater Med Journal subject: ENGENHARIA BIOMEDICA Year: 2022 Type: Article Affiliation country: Japan

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Choroidal Neovascularization / Ranibizumab Limits: Animals Language: En Journal: J Mater Sci Mater Med Journal subject: ENGENHARIA BIOMEDICA Year: 2022 Type: Article Affiliation country: Japan